Singular spectrum analysis filtering and Fourier inversion: an efficient and fast way to improve resolution and quality of current density maps with low-cost Hall scanning systems

We provide a Biot–Savart inversion scheme that, for any two-dimensional, or bulk with planar crystallization, high-temperature superconducting (HTS) sample, determines current density maps with a higher resolution and accuracy than previous procedures and at a fraction of its computational cost. The starting point of our scheme is a Hall scanning microscopy map of the out-of-plane component of the magnetic field generated by the current. Such maps are noisy in scans of real samples with commercial-grade equipment, and their error is the limiting factor in any Biot–Savart inversion scheme. The main innovation of our proposed scheme is a singular spectrum analysis (SSA) filtering of the Hall probe maps, which cancels measurement errors such as noise or drifts without introducing any artifacts in the field map. The SSA filtering of the Hall probe data is so successful in this task that the resulting magnetic field map does not require an overdetermined QR inversion, allowing Fourier inversion of the Biot–Savart problem. Our implementation of SSA filtering of the Hall scan measurements, followed by Biot–Savart inversion using the fast Fourier transform (FFT), is applied to both simulations and real samples of HTS tape stacks. The algorithm works in cases where ill conditioning ruled out the application of Fourier inversion, and achieves a finer resolution for a fraction of the cost of the QR inversion used to date. The computation passes physical and statistical validity tests in all cases, and in three-dimensional samples it is shown to yield the average, with a depth-dependent weight, of the current density circulating in the different layers of the sample.We acknowledge the financial support from the Spanish Ministry of Economy and Competitiveness through the Severo Ochoa Programme (SEV-2015-0496), CONSOLIDER Excellence Network (MAT2015-68994-REDC), COACHSUPENERGY project (MAT2014-51778-C2-1-R, co-financed by FEDER), GAP project (MTM2015-69135-P) and SUPERINKS project (RTC-2015-3640-3, co-financed by FEDER); the European Union for the FASTGRID project (H2020-NMBP-18-2016-IA-72109) and WPMAG 5 (H2020-EUROfusion); and the Catalan Government with 2017-SGR-932, 2014-SGR-753 and Xarmae

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd